Article

Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations

2020-08-06

Abstract excerpt

Despite the effectiveness of antiretroviral (ARV) therapy, virological failure can occur in some HIV-1 infected patients in the absence of mutations in the proteins targeted by these drugs. We previously reported that, in vitro , the lab-adapted NL4-3 strain of HIV-1 can acquire resistance to the integrase inhibitor dolutegravir (DTG) by acquiring mutations in the envelope glycoprotein (Env) that enhance the abil...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 68f92d91-2e7b-56a6-b18c-b50180fadd93
DOI: 10.1101/2020.08.06.239350

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein MutationsDOI 10.1101/2020.08.06.239350Read

Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations.Semantic proximity Read

HIV-1 antiretroviral resistance: scientific principles and clinical applications.Semantic proximity Read

Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)Semantic proximity Read

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.Semantic proximity Read

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase InhibitorsSemantic proximity Read

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug ResistanceSemantic proximity Read

Dolutegravir inhibits HIV-1 Env evolution in primary human cells.Semantic proximity Read

HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre longitudinal study (DTG RESIST)Semantic proximity Read

Dolutegravir resistance mutations: lessons from monotherapy studies.Semantic proximity Read

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceSemantic proximity Read

Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance.Semantic proximity Read